MORE THAN MONEY. WE HELP YOU MOVE FROM IDEA TO IMPACT.
BETA.05
500,000 DKK
6-9 months acceleration phase
BETA.10
1,000,000 DKK
9-12 months acceleration phase
HOW WE ACCELERATE INNOVATION
The BETA.HEALTH Innovation Model forms the foundation of how we accelerate clinical innovation projects that receive a grant through our program.
The model is built around three core elements, each with three key areas, representing the 9 central themes and competencies we focus on when developing and maturing clinical innovation.
At the beginning of the acceleration program, each project – together with its BETA.Partner – assesses its current status using our Innovation Readiness Level (IRL) scale across all nine key areas.
This shared assessment provides a visual and strategic overview of the project’s overall maturity and helps identify where support and focus are most needed during the program.
WHAT YOU GET BEYOND FUNDING
Our team guides you through the acceleration phase, tailoring activities to your project's stage and needs, as well as your team's competencies.
COMMUNICATION AND PITCH SUPPORT
Help articulating your project's value to stakeholders.
BUSINESS MODELLING
Tools and coaching to clarify your project's value and pathways to scale.
PEER NETVÆRK
Connect with other hospital-based innovators across Denmark.
EXPERT SPARRING
Regular 1:1 sessions with your BETA. PARTNER and external advisors.
CLINICAL VALIDATION
Guidance on navigating testing, data access, and compliance.
WORKSHOPS & TOOLS
Targeted sessions on strategy, funding, regulation – and more!
ACCELERATOR PROCESS
KICK-OFF BOOTCAMP
6-9 MONTHS PROJECT DEVELOPMENT
Graduation PITCH
2 day project kick-off – planning and scoping of the acceleration phase with your BETA.Partner
All projects present at our Graduation Pitch Event marking the end of the acceleration phase
Ongoing support and sparring with your BETA.Partner focussing on selected development themes
"
Through BETA.HEALTH, we transformed ATHENA from a proof-of-concept into a clinical solution ready for EPIC integration, clinical validation, and regulatory scaling. The accelerator program gave us access to expert sparring, a clear commercialization strategy, IP, and the partnerships needed to prepare ATHENA for spin-out.
Katrine Bredahl Buggeskov
MD, PhD, Associate Professor in Medical Data, Rigshospitalet
